Storia in 5 fonti

Theravance, after clinical setbacks, agrees to $929M buyout

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Theravance, after clinical setbacks, agrees to $929M buyout

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.

originale

Timeline cronologica

lunedì 29 giugno 2026·biopharmadive.com
Theravance, after clinical setbacks, agrees to $929M buyout
The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.
lunedì 29 giugno 2026·morningstar.com
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

Theravance, after clinical setbacks, agrees to $929M buyout

Confronto fonti

Theravance, after clinical setbacks, agrees to $929M buyout

Timeline cronologica

Theravance, after clinical setbacks, agrees to $929M buyout

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT

Zymeworks to acquire troubled biotech Theravance in $929M deal

Zymeworks acquires struggling Theravance for $929M

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition - Theravance Biopharma (NASDAQ

THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN…

Zymeworks to acquire troubled biotech Theravance in $929M deal

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition - Theravance Biopharma (NASDAQ

Zymeworks acquires struggling Theravance for $929M